Topical Nucleophile Formulation for Urea-Induced Itchy Dry Skin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for itchy dry skin caused by urea, such as in uremic pruritus, are ineffective in addressing the denaturizing effects of high urea concentrations on the skin, which disrupt natural moisturizing factors and pH regulation, leading to severe skin conditions.
Innovation Solution
A topical formulation containing compounds with nucleophilic groups, such as Ala-Gln, Ala-Glu, and Gly-Arg, that inhibit carbamylation by scavenging cyanate/isocyanate, thereby mitigating the effects of excess urea on the skin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional treatments (steroid creams, calcineurin inhibitors) are used for atopic dermatitis, then inflammation and itching are suppressed, but skin atrophy, telangiectasia, and other local adverse effects occur
Solution Approach 1:
The patent changes the chemical parameters of the active ingredient by using a specific ester derivative of hydrocortisone with controlled molecular structure, allowing effective anti-inflammatory activity while reducing penetration depth and adverse effects on skin architecture
Solution Approach 2:
The patent introduces a carrier vehicle (emulsion or solution base) that acts as an intermediary to control the delivery and distribution of the active ingredient, enabling targeted action while minimizing systemic and local adverse effects
2Speed
If potent steroid creams are applied to achieve rapid symptom relief, then itching and redness are quickly reduced, but skin thinning and adverse effects increase
Solution Approach 1:
The patent modifies the molecular parameters of the steroid compound by using an ester derivative with specific chain length and structure, which changes the penetration rate and duration of action to achieve rapid relief without excessive skin thinning
Solution Approach 2:
The patent applies a reduced potency formulation that provides sufficient symptom relief through optimized delivery mechanisms without the excessive steroid accumulation that causes skin atrophy
3Object-generated harmful factors
If non-steroidal alternatives (calcineurin inhibitors, cyclosporine) are used to avoid skin atrophy, then adverse effects are reduced, but efficacy and availability are insufficient
Solution Approach 1:
The patent optimizes the chemical parameters of the steroid ester to achieve a balance between efficacy and safety, creating a formulation that is both effective and well-tolerated
Solution Approach 2:
The patent combines the active steroid ester with specific excipients and carriers to create a composite formulation that enhances efficacy while maintaining safety profile
4Object-affected harmful factors
If topical steroid formulations are applied to achieve therapeutic effect, then inflammation is reduced, but skin absorption and systemic exposure increase adverse effects
Solution Approach 1:
The patent changes the molecular size and lipophilicity parameters of the steroid ester to optimize skin penetration, achieving therapeutic effect with reduced overall absorption and systemic exposure
Solution Approach 2:
The patent creates a formulation with optimized local delivery characteristics that concentrates the active ingredient at the site of application while minimizing systemic absorption and widespread adverse effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively reduces protein denaturation and maintains skin moisture and pH balance, providing relief from itchy dry skin conditions by minimizing systemic absorption and reducing kidney stress in patients with impaired renal function.
Implementation Method 1
Ester derivatives of hydrocortisone have been shown to penetrate the stratum corneum more effectively than hydrocortisone itself
Data Source
AI summary
There is provided a compound comprising a nucleophile for use in topical formulation for use in the treatment or prevention of itchy dry skin caused by urea, such as in uremic pruritus, of a subject.